Teligent Inc. (NASDAQ:TLGT)’s share price traded down 2.4% on Friday . The stock traded as low as $8.08 and last traded at $8.09, with a volume of 220,079 shares changing hands. The stock had previously closed at $8.29.

Several equities analysts have weighed in on the stock. JMP Securities assumed coverage on shares of Teligent in a report on Wednesday, June 29th. They set a “hold” rating on the stock. Zacks Investment Research raised shares of Teligent from a “hold” rating to a “buy” rating and set a $9.25 price target on the stock in a report on Tuesday, July 12th. Oppenheimer Holdings Inc. reaffirmed a “hold” rating on shares of Teligent in a report on Tuesday, April 26th. TheStreet raised shares of Teligent from a “sell” rating to a “hold” rating in a report on Thursday, June 23rd. Finally, Raymond James Financial Inc. assumed coverage on shares of Teligent in a report on Wednesday, June 22nd. They set a “strong-buy” rating and a $11.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $9.81.

The company’s market cap is $431.37 million. The stock’s 50 day moving average is $6.89 and its 200-day moving average is $6.22.

Teligent (NASDAQ:TLGT) last posted its quarterly earnings data on Thursday, April 28th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.05. The company had revenue of $15.70 million for the quarter, compared to analyst estimates of $14.33 million. The business’s quarterly revenue was up 46.7% compared to the same quarter last year. On average, equities analysts expect that Teligent Inc. will post $0.01 EPS for the current year.

An institutional investor recently bought a new position in Teligent stock. Russell Frank Co acquired a new stake in shares of Teligent Inc. (NASDAQ:TLGT) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 410,606 shares of the company’s stock, valued at approximately $3,605,000. Russell Frank Co owned approximately 0.78% of Teligent as of its most recent filing with the SEC.

Teligent, Inc, formerly IGI Laboratories, Inc, is a specialty generic pharmaceutical company. The Company markets and sells generic injectable pharmaceutical products under its own label in the United States and Canada. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.